tiprankstipranks
Advertisement
Advertisement

KYMR Stock Latest News

Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
The FlyKymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
4d ago
KYMR
Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
PremiumThe Fly
Kymera Therapeutics reports Q1 EPS (71c), consensus (86c)
4d ago
KYMR
FDA grants fast track designation to Kymera Therapeutics KT-621
PremiumThe Fly
FDA grants fast track designation to Kymera Therapeutics KT-621
21d ago
KYMR
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
PremiumRatings
Reaffirming Buy: Kymera’s Protein Degradation Platform and KT-621 Pipeline Advance Underpin Long-Term Value
24d ago
KYMR
Kymera Therapeutics announces Gilead option exercise to license KT-200
PremiumThe Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
25d ago
GILD
KYMR
Kymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
PremiumThe FlyKymera Therapeutics presents results from BroADen Phase 1b AD trial of KT-621
1M ago
KYMR
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
Premium
Company Announcements
Kymera Therapeutics Updates Bylaws on Federal Securities Litigation
1M ago
8K
KYMR
Kymera Therapeutics assumed with a Buy at Jefferies
Premium
The Fly
Kymera Therapeutics assumed with a Buy at Jefferies
2M ago
KYMR
Kymera Therapeutics price target raised to $128 from $90 at UBS
PremiumThe Fly
Kymera Therapeutics price target raised to $128 from $90 at UBS
2M ago
KYMR
Kymera Therapeutics price target raised to $100 from $95 at Stephens
PremiumThe Fly
Kymera Therapeutics price target raised to $100 from $95 at Stephens
2M ago
KYMR
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
PremiumRatings
Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk-Reward
2M ago
KYMR
Kymera Therapeutics price target raised to $120 from $110 at Citi
PremiumThe Fly
Kymera Therapeutics price target raised to $120 from $110 at Citi
2M ago
KYMR
Kymera Therapeutics Signals Strong Momentum In Earnings Call
PremiumCompany AnnouncementsKymera Therapeutics Signals Strong Momentum In Earnings Call
2M ago
KYMR
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
Premium
Company Announcements
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors
2M ago
KYMR
Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029
Premium
Ratings
Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029
2M ago
KYMR
Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley
PremiumThe Fly
Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley
2M ago
KYMR
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler
PremiumThe Fly
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler
2M ago
KYMR
Kymera Therapeutics Establishes New $500 Million ATM Program
PremiumCompany Announcements
Kymera Therapeutics Establishes New $500 Million ATM Program
2M ago
8K
KYMR
Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)
PremiumThe Fly
Kymera Therapeutics reports Q4 EPS (97c), consensus (79c)
2M ago
KYMR
KYMR Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsKYMR Upcoming Earnings Report: What to Expect?
3M ago
KYMR
Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market
Premium
Ratings
Kymera Therapeutics: KT-621’s Differentiated Efficacy and Safety Profile Underpins Attractive Risk-Reward in Emerging Oral Atopic Dermatitis Market
3M ago
KYMR
Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621
Premium
The Fly
Kymera Therapeutics initiates dosing in BREADTH Phase 2b trial of KT-621
3M ago
KYMR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >